antifungal resistance – Page 5

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

Researchers in Iran studied 136 hospital patients to identify different types of Candida fungal infections using a molecular laboratory technique called PCR-RFLP. They found that while Candida albicans remained the most common species, other Candida species were increasingly prevalent in hospitalized patients. The study developed a cost-effective diagnostic method that could help developing countries identify these fungal infections faster and more accurately, though the dangerous multidrug-resistant Candida auris was not found in their samples.

Detection of Multiple Nosocomial Trichosporon asahii Transmission Events via Microsatellite Typing Assay, South America

mycolabadmin

Researchers developed a test to identify different strains of a dangerous fungus called Trichosporon asahii that causes serious infections in hospitals. Using this test on samples from South America, they discovered that multiple patients in different hospitals were infected with genetically identical strains, suggesting the fungus was spreading between patients. This typing method is faster and cheaper than other genetic tests, making it useful for hospitals in countries with limited resources to track and control fungal outbreaks.

Investigation of the antifungal activity of panobinostat, tamoxifen, and miltefosine alone and in combination with some conventional antifungal drugs against fluconazole-resistant Candida species

mycolabadmin

Researchers tested whether three cancer drugs (panobinostat, tamoxifen, and miltefosine) could enhance the effectiveness of common antifungal medications against drug-resistant yeast infections. When combined with antifungals, some of these cancer drugs showed promise in killing resistant Candida species, though the effectiveness varied depending on which type of yeast was being treated. These findings suggest that combination therapies using already-approved drugs could help treat difficult fungal infections in cancer patients.

Prevalence of Candida and Other Yeasts in Vulvovaginal Infections during Pregnancy: A 10-Year Serbian Survey

mycolabadmin

This study examined yeast infections in pregnant Serbian women over 10 years, finding that nearly half had positive tests. While Candida albicans was most common, many other yeast species were also identified, some of which are resistant to common antifungal medications. Using advanced laboratory techniques (MALDI-TOF MS), researchers found more accurate identification was possible, which is important since different yeasts require different treatments, especially during pregnancy when some medications can harm the baby.

Characteristics of Chrysosporium spp. Pathogens Causing Skin Mycoses in Horses

mycolabadmin

Researchers in Kazakhstan discovered two new fungal pathogens affecting horses’ skin for the first time. These fungi, called Chrysosporium kreiselii and Chrysosporium zonatum, cause skin lesions and dandruff in horses. One strain is resistant to most antifungal medications, making it particularly challenging to treat.

Past, present and future of antifungals: Advancements in mechanisms of action and resistance

mycolabadmin

Fungal infections are a growing global health threat, especially for people with weakened immune systems, causing millions of deaths annually. Currently available antifungal drugs are limited and increasingly face resistance, making them less effective over time. This special collection of research papers explores new approaches to treating fungal infections, including novel drugs, combination therapies, and alternative treatments to overcome resistance. Scientists and doctors hope these advances will help save more lives by providing better options for treating serious fungal diseases.

Interaction with amoeba drives virulence-associated phenotypes in the Candida haemulonii complex

mycolabadmin

Researchers discovered that when fungal pathogens called Candida haemulonii are exposed to soil amoebae in laboratory conditions, they develop enhanced disease-causing abilities. These fungi undergo multiple changes including forming stronger protective biofilms, producing more virulence factors, and becoming harder to kill by immune defenses. This suggests that fungal pathogens might develop some of their dangerous traits not from infecting humans, but from surviving in soil environments where they must evade predatory organisms like amoebae.

Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods

mycolabadmin

Researchers compared three different laboratory methods for testing how well antifungal drugs work against common yeast infections. They tested 22 different yeast strains including Candida species using CLSI, EUCAST, and Sensititre YeastOne methods. The methods showed strong agreement overall, but some newer antifungal drugs like ibrexafungerp showed more variation between methods. The findings suggest these methods are reliable for guiding treatment decisions, but further standardization is needed for newer drugs.

Genome characterization of Trichophyton mentagrophytes genotype VII strain PG12DES from Italy

mycolabadmin

Researchers in Italy analyzed the genetic makeup of a fungus called Trichophyton mentagrophytes that causes skin infections and appears to spread between people through sexual contact. The fungal strain studied was susceptible to all tested antifungal medications and shared similarities with a strain previously found in Moldova. This study helps doctors understand how this emerging fungal infection spreads globally and whether it’s developing resistance to treatments.

Clinical aspects and recent advances in fungal diseases impacting human health

mycolabadmin

Fungal infections affect over a billion people worldwide and are becoming harder to treat due to growing resistance to antifungal medications. The review discusses major challenges in detecting and treating these infections, including difficulty in diagnosis and limited awareness among healthcare providers. New antifungal drugs are being developed and approved to address these challenges, but a comprehensive approach involving better awareness, improved testing, and responsible medication use is needed.

Research Topic: antifungal resistance